MaltSci 麦伴科研

Appearance

Popular Reports / endocrinology

This report is written by MaltSci based on the latest literature and research findings

How does diabetes affect multiple organ systems? ​

Abstract ​

Diabetes mellitus is a chronic metabolic disorder characterized by persistent hyperglycemia, with a rapidly increasing global prevalence that poses significant public health challenges. The systemic nature of diabetes leads to multifaceted complications affecting various organ systems, including the cardiovascular, renal, neurological, and ocular systems. This review synthesizes current research findings to provide a comprehensive overview of the mechanisms by which diabetes induces organ-specific damage. Key pathophysiological processes include metabolic dysregulation, oxidative stress, and inflammation, which interact to exacerbate complications such as diabetic cardiomyopathy, nephropathy, neuropathy, and retinopathy. Advances in molecular research have identified critical pathways, such as the mTOR signaling pathway, that contribute to these complications and present potential therapeutic targets. Clinical management strategies have evolved to include pharmacological interventions, lifestyle modifications, and surgical options, emphasizing the importance of integrated care approaches that address both glycemic control and the prevention of multi-organ complications. The report concludes with recommendations for future research directions, including the exploration of novel biomarkers and targeted therapies, to enhance patient outcomes and reduce the burden of diabetes-related complications. Understanding the interconnections between these organ systems is vital for developing effective interventions that improve the quality of life for individuals living with diabetes.

Outline ​

This report will discuss the following questions.

  • 1 Introduction
  • 2 The Impact of Diabetes on the Cardiovascular System
    • 2.1 Pathophysiology of Diabetic Cardiovascular Disease
    • 2.2 Clinical Implications and Management Strategies
  • 3 The Renal Complications of Diabetes
    • 3.1 Diabetic Nephropathy: Mechanisms and Risk Factors
    • 3.2 Current Approaches to Prevention and Treatment
  • 4 Neurological Effects of Diabetes
    • 4.1 Diabetic Neuropathy: Types and Symptoms
    • 4.2 Management and Therapeutic Options
  • 5 Ocular Complications Associated with Diabetes
    • 5.1 Diabetic Retinopathy: Pathogenesis and Screening
    • 5.2 Treatment Modalities and Outcomes
  • 6 Other Organ Systems Affected by Diabetes
    • 6.1 The Impact on the Gastrointestinal System
    • 6.2 Effects on the Immune System
  • 7 Conclusion

1 Introduction ​

Diabetes mellitus, a chronic metabolic disorder characterized by persistent hyperglycemia, has emerged as a global epidemic with profound implications for public health. According to the International Diabetes Federation, the number of individuals diagnosed with diabetes is expected to rise to 700 million by 2045, highlighting the urgent need for comprehensive understanding and management of this condition [1]. The disease results from defects in insulin secretion, insulin action, or both, leading to a cascade of metabolic dysfunctions that adversely affect multiple organ systems, including the cardiovascular, renal, neurological, and ocular systems [2][3]. The systemic nature of diabetes necessitates a holistic approach to its management, focusing not only on glycemic control but also on the prevention of multi-organ complications that significantly contribute to morbidity and mortality [4].

The pathophysiological mechanisms underlying diabetes-related complications are complex and multifaceted. Hyperglycemia, dyslipidemia, and hypertension are key factors that interact with the duration and type of diabetes to induce organ-specific damage [2]. For instance, diabetic nephropathy is characterized by progressive renal dysfunction due to glomerular injury, while diabetic retinopathy involves retinal vascular abnormalities that can lead to vision loss [3]. Neuropathy, another common complication, manifests in various forms, affecting both peripheral and autonomic nervous systems [5]. Furthermore, the involvement of diabetes in other organ systems, such as the gastrointestinal and immune systems, has begun to receive increased attention, emphasizing the need for a comprehensive understanding of its systemic effects [6].

Current research has provided valuable insights into the molecular and cellular mechanisms driving these complications. Studies have highlighted the role of lipid metabolism in mediating tissue-specific damage, suggesting that alterations in lipid profiles may serve as potential biomarkers for diabetic complications [7]. Additionally, the application of advanced techniques such as single-cell RNA sequencing has enabled a deeper exploration of the cellular heterogeneity and pathogenesis associated with diabetes [8]. These findings underscore the importance of identifying organ-specific therapeutic targets to improve patient outcomes and reduce the burden of diabetes-related complications [4].

This report is organized into several sections that will systematically address the impact of diabetes on various organ systems. The second section will delve into the cardiovascular system, discussing the pathophysiology of diabetic cardiovascular disease and current management strategies. The subsequent section will focus on renal complications, particularly diabetic nephropathy, exploring the underlying mechanisms and preventive measures. The neurological effects of diabetes will be examined next, highlighting the different types of diabetic neuropathy and available therapeutic options. The ocular complications associated with diabetes, specifically diabetic retinopathy, will be discussed in detail, including its pathogenesis and treatment modalities. Finally, the report will explore other affected organ systems, such as the gastrointestinal and immune systems, before concluding with a synthesis of the findings and recommendations for a holistic approach to diabetes management.

By synthesizing current research findings, this review aims to provide a comprehensive overview of the systemic effects of diabetes on multiple organ systems, reinforcing the critical need for an integrated approach to diabetes care that encompasses both glycemic control and the prevention of multi-organ complications. Understanding the interconnections between these systems will facilitate the development of targeted interventions, ultimately improving the quality of life for individuals living with diabetes.

2 The Impact of Diabetes on the Cardiovascular System ​

2.1 Pathophysiology of Diabetic Cardiovascular Disease ​

Diabetes mellitus is a complex endocrine disorder that significantly impacts multiple organ systems, particularly the cardiovascular system. The pathophysiology of diabetic cardiovascular disease is multifaceted, involving various biochemical and structural alterations that ultimately lead to increased morbidity and mortality among diabetic patients.

One of the primary effects of diabetes on the cardiovascular system is the development of diabetic cardiomyopathy, which occurs in the absence of other cardiovascular risk factors such as hypertension or atherosclerosis. This condition is characterized by impaired cardiac function due to metabolic disturbances induced by prolonged hyperglycemia. Specifically, diabetes leads to alterations in the extracellular matrix (ECM) of the heart, resulting in fibrosis and stiffness, which contribute to reduced cardiac performance [9].

Diabetes also causes vascular endothelial dysfunction, a condition that plays a critical role in the development of cardiovascular complications. Endothelial dysfunction is associated with increased oxidative stress and inflammation, which can lead to atherosclerosis and subsequent coronary artery disease [10]. The involvement of the mammalian target of rapamycin (mTOR) signaling pathways has been noted, as these pathways regulate insulin signaling and can become dysregulated in diabetes, further exacerbating cardiovascular complications [11].

Additionally, diabetes is associated with a range of cardiac electrical disturbances, including increased susceptibility to arrhythmias such as atrial fibrillation and ventricular arrhythmias. These arrhythmias result from autonomic dysfunction and structural remodeling of the heart, which are common in diabetic patients [12]. The chronic hyperglycemic environment leads to metabolic alterations that impair cardiac contractility and increase the risk of ischemic events [13].

The relationship between diabetes and cardiovascular disease is further complicated by the systemic nature of the disease, which affects various organs, including the kidneys and eyes. Diabetic nephropathy and retinopathy are common complications that can also influence cardiovascular health. For instance, diabetic retinopathy is associated with an increased risk of systemic vascular complications, including coronary heart disease and heart failure [14].

Moreover, the activation of specific pathways, such as those involving Ca2+/calmodulin-dependent protein kinase II (CaMKII), has been implicated in the progression of diabetes and its cardiovascular effects. CaMKII is activated by elevated intracellular calcium levels and plays a crucial role in various organ systems, including the heart, where it can affect contractile function and promote pathological remodeling [4].

In summary, diabetes affects multiple organ systems through a variety of mechanisms, particularly impacting the cardiovascular system. The resultant complications, including diabetic cardiomyopathy, endothelial dysfunction, and arrhythmias, underscore the importance of early intervention and comprehensive management strategies to mitigate the cardiovascular risks associated with diabetes. The ongoing research into the underlying pathophysiological mechanisms is vital for developing targeted therapies aimed at reducing the burden of diabetic cardiovascular disease.

2.2 Clinical Implications and Management Strategies ​

Diabetes mellitus significantly impacts multiple organ systems, particularly the cardiovascular system, which is highly susceptible to the complications arising from this disease. The relationships between diabetes and cardiovascular disease are multifaceted, encompassing various pathophysiological mechanisms that contribute to increased morbidity and mortality among diabetic patients.

One of the primary effects of diabetes on the cardiovascular system is the development of diabetic vascular disease and diabetic cardiomyopathy. These conditions are characterized by structural and functional alterations in the heart and blood vessels, primarily due to the metabolic disturbances associated with diabetes. For instance, hyperglycemia, oxidative stress, and inflammation lead to endothelial dysfunction, which is a critical factor in the progression of atherosclerosis and cardiovascular complications (Kovacic et al. 2014) [10]. Furthermore, diabetes can induce changes in cardiomyocyte metabolism and function, exacerbating the risk of heart failure and other cardiovascular diseases (Strocchi et al. 2025) [15].

The mammalian target of rapamycin (mTOR) signaling pathway plays a crucial role in the cardiovascular complications of diabetes. mTOR regulates insulin signaling, endothelial cell survival, and cardiomyocyte proliferation. However, its dysregulation can lead to insulin resistance and contribute to the adverse effects on cardiovascular health observed in diabetic patients (Chong & Maiese 2012) [11]. This highlights the importance of understanding the complex interplay between diabetes and cardiovascular function to develop targeted therapeutic strategies.

Clinical management of diabetes-related cardiovascular complications has evolved, with recent studies emphasizing the role of specific pharmacological agents. Glucagon-like peptide-1 (GLP-1) receptor agonists, dipeptidyl peptidase-4 (DPP-4) inhibitors, and sodium-glucose cotransporter 2 (SGLT2) inhibitors have demonstrated beneficial effects on cardiovascular outcomes in diabetic patients. These therapies not only improve glycemic control but also reduce the incidence of serious cardiovascular events, including myocardial infarction and stroke (Gajos 2018) [16]. The results from large randomized clinical trials, such as EMPA-REG and LEADER, underscore the importance of these new therapeutic strategies in managing cardiovascular risk in diabetes (Gajos 2018) [16].

Moreover, lifestyle interventions and bariatric surgery have shown promise in improving cardiovascular outcomes in diabetic patients. Bariatric surgery, in particular, has been associated with significant long-term benefits on organ function and has the potential to reverse tissue fibrosis, which is a common complication of diabetes affecting the heart, liver, and kidneys (Ding et al. 2022) [1].

In conclusion, diabetes exerts profound effects on multiple organ systems, especially the cardiovascular system, through various mechanisms including metabolic dysregulation, oxidative stress, and inflammation. The clinical implications of these effects necessitate comprehensive management strategies that incorporate both pharmacological and non-pharmacological approaches to mitigate the risks associated with diabetes-related cardiovascular disease. Understanding the underlying pathophysiology and the potential therapeutic targets remains critical for improving patient outcomes in this population.

3 The Renal Complications of Diabetes ​

3.1 Diabetic Nephropathy: Mechanisms and Risk Factors ​

Diabetes mellitus has profound adverse effects on multiple organ systems, with the kidneys being significantly impacted, leading to a condition known as diabetic nephropathy. This complication is one of the most common associated with diabetes and represents a major cause of end-stage renal disease (ESRD). The pathogenesis of diabetic nephropathy is multifactorial, involving a complex interplay of metabolic derangements, hemodynamic alterations, and inflammatory processes.

In both type 1 and type 2 diabetes, the kidney damage is primarily driven by hyperglycemia, dyslipidaemia, and hypertension, along with the duration and type of diabetes. These factors contribute to distinct pathophysiological changes within the renal tissues, leading to the development of diabetic nephropathy, which is characterized by glomerular hyperfiltration, mesangial expansion, and ultimately, renal fibrosis [2][17]. The inflammatory component of diabetes is increasingly recognized as a crucial factor in the progression of renal injury. Various inflammatory molecules, such as cytokines and chemokines, are involved in the pathogenesis of diabetic nephropathy, linking metabolic disturbances with renal damage [18][19].

The role of the complement system has also emerged as a significant factor in diabetic nephropathy. Studies have shown that components such as mannose-binding lectin (MBL) are associated with the progression of renal injury in the context of diabetes, suggesting that modulating the complement system could offer new therapeutic avenues [20]. Furthermore, the mammalian target of rapamycin (mTOR) pathway has been implicated in the progression of diabetic nephropathy by promoting inflammation and oxidative stress, indicating that targeting this pathway may provide beneficial effects in managing the disease [21].

Diabetic nephropathy not only leads to kidney dysfunction but is also associated with increased cardiovascular morbidity and mortality. The condition is often accompanied by other diabetic microvascular complications, such as diabetic retinopathy and neuropathy, which share common metabolic pathways [14]. The presence of diabetic nephropathy is a strong predictor of systemic vascular complications, highlighting the interconnected nature of these complications in diabetic patients [14].

In summary, diabetes adversely affects the kidneys through a combination of metabolic dysregulation, hemodynamic changes, and inflammatory processes, culminating in diabetic nephropathy. This condition necessitates a multifaceted therapeutic approach aimed at controlling blood glucose levels, managing blood pressure, and addressing the inflammatory components to mitigate renal damage and improve patient outcomes.

3.2 Current Approaches to Prevention and Treatment ​

Diabetes mellitus is a multifaceted disease that adversely affects multiple organ systems, particularly the kidneys, heart, and eyes. The renal complications of diabetes, specifically diabetic nephropathy, represent one of the most significant challenges in managing the disease, given their prevalence and the associated morbidity and mortality.

Diabetes impacts the kidneys primarily through a combination of metabolic insults including hyperglycemia, dyslipidemia, and hypertension. These factors contribute to a unique pathophysiology that varies between type 1 and type 2 diabetes, leading to organ-specific damage. In diabetic nephropathy, progressive sclerosis and fibrosis of the kidney tissue occur, often due to the overactivity of the transforming growth factor-beta (TGF-β) system and vascular endothelial growth factor (VEGF) signaling pathways [22]. This progression can result in significant renal dysfunction and ultimately chronic renal failure.

The treatment landscape for diabetic nephropathy has historically been limited. While angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs) have been effective in managing blood pressure and slowing the progression of kidney disease, there remains a pressing need for additional therapeutic options. Current research is exploring the multifactorial etiology of diabetic nephropathy, focusing on the interplay of various pathogenic pathways [22]. There is an emerging emphasis on the role of inflammation in renal injury, with inflammatory mediators such as adipokines and cytokines being implicated in the pathogenesis of nephropathy [19].

Recent advancements have highlighted the potential of bariatric surgery as a treatment modality for diabetic complications, including renal fibrosis. This surgical intervention has shown promise in reversing the effects of diabetes on multiple organ systems, particularly the kidneys, by addressing underlying metabolic derangements and promoting weight loss [1]. Moreover, the role of microRNAs as therapeutic targets is gaining attention, with studies suggesting that these non-coding RNAs may play a significant role in regulating the pathological processes associated with diabetic complications [23].

Preventive strategies for diabetic nephropathy focus on intensive glycemic control and management of cardiovascular risk factors. Effective control of hypertension and dyslipidemia, alongside lifestyle modifications, can significantly reduce the risk of renal disease progression [22]. However, adherence to these interventions can be challenging due to patient compliance issues and potential adverse drug reactions [1].

In summary, diabetes mellitus affects multiple organ systems through a complex interplay of metabolic derangements, leading to specific complications such as diabetic nephropathy. Current approaches to prevention and treatment emphasize the importance of managing blood glucose levels, controlling associated risk factors, and exploring innovative therapeutic strategies, including surgical interventions and the targeting of molecular pathways involved in disease progression. Continued research is essential to develop more effective treatments and improve patient outcomes in those suffering from diabetic complications.

4 Neurological Effects of Diabetes ​

4.1 Diabetic Neuropathy: Types and Symptoms ​

Diabetes mellitus has profound effects on multiple organ systems, particularly through the development of diabetic neuropathy, which is a heterogeneous group of disorders that affects both somatic and autonomic components of the nervous system. Diabetic neuropathy is characterized by nerve damage resulting from prolonged exposure to high blood glucose levels, leading to a variety of symptoms that can significantly impair the quality of life of affected individuals.

The pathophysiology of diabetic neuropathy is complex and involves several mechanisms. In both type 1 and type 2 diabetes, tissue damage is organ-specific and results from a combination of metabolic insults, including hyperglycemia, dyslipidemia, and hypertension. These factors contribute to distinct pathophysiological processes that underlie complications such as diabetic kidney disease, diabetic retinopathy, and diabetic neuropathy [2].

Neuropathic symptoms in diabetic patients can manifest in various forms, including pain, sensory loss, muscle weakness, and autonomic dysfunction. Common types of diabetic neuropathy include peripheral neuropathy, which affects the limbs, and autonomic neuropathy, which can disrupt functions such as heart rate, blood pressure regulation, and gastrointestinal motility [24]. Additionally, there is increasing recognition of central nervous system involvement in diabetic neuropathy, indicating that diabetes affects the entire nervous system rather than being limited to peripheral nerves [25].

The symptoms of diabetic neuropathy can be classified into two main categories: sensory and motor symptoms. Sensory symptoms often include pain, tingling, and numbness, particularly in the feet and hands, while motor symptoms may present as weakness and loss of coordination [26]. Autonomic symptoms can lead to gastrointestinal issues such as gastroparesis, bladder dysfunction, and sexual dysfunction [27].

The underlying mechanisms contributing to diabetic neuropathy involve a range of metabolic and inflammatory processes. Hyperglycemia leads to the accumulation of advanced glycation end products (AGEs), which can promote oxidative stress and inflammation, damaging nerve tissues [28]. Additionally, factors such as dyslipidemia and insulin resistance play critical roles in the development and progression of neuropathy [28]. It is important to note that while glycemic control is essential in managing diabetes and its complications, neuropathy can still progress in patients with well-controlled blood glucose levels, suggesting that other mechanisms are also at play [28].

In summary, diabetes mellitus affects multiple organ systems through a complex interplay of metabolic derangements that lead to diabetic neuropathy. This condition presents a range of symptoms that can significantly impair the quality of life, highlighting the importance of early detection and comprehensive management strategies to address both the neurological and systemic complications of diabetes.

4.2 Management and Therapeutic Options ​

Diabetes mellitus significantly impacts multiple organ systems, particularly the nervous system, leading to various complications. Neurological effects of diabetes include cognitive dysfunction, cerebrovascular disease, and increased risk of stroke. The disease has been shown to nearly double a person's risk of stroke and is a major contributor to cerebral small vessel disease and dementia, highlighting the severe consequences diabetes has on brain health[29].

The central nervous system (CNS) is intricately involved in the regulation of energy metabolism and glucose homeostasis. The brain, being a glucose-dependent organ, is susceptible to damage from both hyperglycemia and hypoglycemia. These fluctuations can lead to cognitive impairments and neurological complications, including chronic diabetic encephalopathies that may result in dementia[30]. Furthermore, treatment-related hypoglycemia can have adverse effects on the CNS, exacerbating the cognitive decline associated with diabetes[5].

The mechanisms underlying these neurological effects are complex. Diabetes induces structural and functional changes in the vasculature, resulting in microvascular injury, which is a significant factor in the development of diabetic encephalopathy[31]. The integrity of the blood-brain barrier (BBB) is compromised in diabetes, contributing to neurological dysfunction and cognitive decline. The BBB's role in protecting the brain's microenvironment is crucial, and its injury is linked to the pathogenesis of diabetes-related complications[31].

Management of diabetes-related neurological complications requires a multifaceted approach. Effective glycemic control is essential to prevent both acute and chronic complications. Neurologists and other healthcare providers play a critical role in the routine care of diabetic patients, focusing on preventive strategies to mitigate the harmful effects of diabetes on the brain[29]. This includes regular monitoring of blood glucose levels, management of comorbid conditions, and lifestyle interventions aimed at improving overall health and reducing the risk of neurological decline.

Recent research has underscored the need for organ-specific interventions in treating diabetic complications, particularly those affecting the nervous system. Understanding the pathophysiological mechanisms and the interplay between diabetes and neurological health can lead to the development of targeted therapies that may improve outcomes for patients suffering from diabetes-related cognitive impairments and cerebrovascular diseases[2].

In conclusion, diabetes mellitus exerts profound effects on multiple organ systems, especially the nervous system, leading to significant morbidity. A comprehensive understanding of these effects is essential for developing effective management strategies and therapeutic options to enhance patient outcomes and quality of life.

5 Ocular Complications Associated with Diabetes ​

5.1 Diabetic Retinopathy: Pathogenesis and Screening ​

Diabetes mellitus (DM) is a chronic metabolic disorder that exerts profound effects on multiple organ systems, leading to various complications, particularly in the eyes. Among these, diabetic retinopathy (DR) is a significant ocular complication, characterized by its inflammatory and neurovascular nature, which poses a leading cause of preventable blindness in working-age adults in developed countries. The pathogenesis of diabetic retinopathy involves complex interactions among retinal cells, including photoreceptors, neurons, glial cells, and vascular tissues, all of which are adversely affected by diabetes-induced alterations in cell signaling and blood-retinal barrier integrity [3].

The underlying mechanisms contributing to the development of diabetic retinopathy include hyperglycemia, oxidative stress, and inflammation. Hyperglycemia leads to the accumulation of advanced glycation end products (AGEs) and activates various signaling pathways, including the NF-κB pathway, which is crucial in mediating inflammatory responses. The resulting inflammation disrupts the delicate balance of cellular interactions in the retina, contributing to vascular abnormalities and neuronal dysfunction [32].

Furthermore, diabetes induces significant metabolic changes, including dyslipidemia and hypertension, which compound the risk of developing diabetic complications across different organ systems, including the kidneys and nerves. In particular, diabetic retinopathy reflects widespread microvascular disease not only in the eye but also in vital organs, suggesting a systemic link between ocular and non-ocular complications of diabetes [33].

The screening and early detection of diabetic retinopathy are crucial for preventing vision loss. Traditional methods involve fundus photography and optical coherence tomography (OCT), which allow for the visualization of retinal changes and microvascular damage. The identification of early signs of retinopathy, such as microaneurysms and retinal hemorrhages, is essential for timely intervention [34].

Recent advances in nanotechnology and targeted therapies offer promising avenues for the treatment of diabetic ocular complications. These innovative approaches aim to improve drug delivery systems, enhancing the efficacy of therapeutic agents while minimizing systemic side effects [35].

In summary, diabetes mellitus significantly impacts multiple organ systems, with diabetic retinopathy serving as a critical example of how systemic metabolic dysregulation can lead to severe ocular complications. Understanding the pathogenesis of diabetic retinopathy is essential for developing effective screening methods and treatment strategies to mitigate its impact on patients' quality of life [14][36].

5.2 Treatment Modalities and Outcomes ​

Diabetes mellitus (DM) is a chronic metabolic disorder that significantly impacts various organ systems, leading to a multitude of complications. Among these, ocular complications are particularly noteworthy due to their severity and impact on patients' quality of life. Diabetic retinopathy (DR), cataracts, keratopathy, and glaucoma are some of the major ocular manifestations associated with diabetes. These conditions are not only sources of considerable physical discomfort but also impose a substantial economic burden on healthcare systems [35].

The pathogenesis of diabetic ocular complications is multifactorial. Hyperglycemia plays a critical role in the development of these conditions, leading to structural and functional alterations in the eye. For instance, diabetic retinopathy is characterized by profound vascular abnormalities and loss of the blood-retinal barrier, which are exacerbated by diabetes-induced changes in cell signaling interactions. This results in impaired neuronal function and ultimately vision loss [3]. The retina, being a highly metabolically active tissue, is particularly vulnerable to the metabolic derangements associated with diabetes [3].

Research has demonstrated that the accumulation of sorbitol, mediated by the enzyme aldose reductase, contributes to ocular damage in diabetes. This accumulation is implicated in the pathogenesis of both cataracts and retinopathy, indicating that targeting this pathway through pharmacological inhibition may prevent ocular complications [37]. Furthermore, inflammation is a significant component of diabetic complications, including those affecting the ocular surface. Low-grade inflammation in diabetic patients can lead to immune dysregulation, affecting the cornea and retina [36].

Innovative treatment modalities utilizing nanotechnology have emerged as promising strategies for managing diabetic ocular complications. These approaches aim to enhance drug delivery specifically to ocular tissues, potentially improving therapeutic outcomes [35]. Additionally, systemic control of diabetes through lifestyle modifications and pharmacotherapy is essential in mitigating ocular complications. The application of anti-inflammatory and vasoprotective agents may also play a role in preserving ocular health [38].

In summary, diabetes affects multiple organ systems, leading to a range of complications, particularly in the ocular region. The interplay of hyperglycemia, inflammation, and metabolic disturbances underpins the pathogenesis of diabetic ocular complications. Advances in treatment modalities, including nanotechnology and systemic management strategies, hold promise for improving outcomes in patients suffering from these debilitating conditions [3][35][37].

6 Other Organ Systems Affected by Diabetes ​

6.1 The Impact on the Gastrointestinal System ​

Diabetes mellitus has significant implications for various organ systems, particularly the gastrointestinal (GI) system. The degree of involvement of different organs, including the GI tract, is influenced by the duration and severity of diabetes, as well as the presence of co-morbidities. Gastrointestinal complications in diabetes can manifest in various forms, including esophageal dysmotility, gastro-esophageal reflux disease (GERD), gastroparesis, enteropathy, non-alcoholic fatty liver disease (NAFLD), and glycogenic hepatopathy [39].

The GI tract can be affected by diabetes through multiple pathophysiological mechanisms. In patients with diabetes, metabolic alterations, neuropathy, and disrupted hormone homeostasis can lead to upper and lower GI symptoms in up to 75% of individuals. These symptoms may involve the esophagus, stomach, intestines, and gallbladder [40]. For instance, diabetic gastroparesis is characterized by symptoms such as early satiety, bloating, vomiting, abdominal pain, and erratic glycemic control. The gold standard for diagnosing this condition is gastric emptying scintigraphy, and management typically includes dietary modifications, maintenance of euglycemia, prokinetics, and sometimes endoscopic or surgical interventions [39].

Moreover, diabetes can lead to enteric neuropathy, which critically affects the enteric nervous system (ENS). This condition disrupts the regulation of GI motility, secretion, and absorption, resulting in dysfunctions such as gastroparesis and irregular bowel habits. The development of enteric neuropathy is attributed to oxidative stress and inflammation, affecting the function of neuronal and glial cells within the ENS [27]. Therefore, it is essential to consider GI symptoms and conduct a comprehensive assessment of GI function in the management of diabetic patients to prevent further complications and enhance their quality of life [40].

Furthermore, diabetes is associated with an increased risk of various GI tract cancers, highlighting the need for vigilance in monitoring GI health in diabetic individuals [40]. The management of GI complications is critical not only for controlling metabolic parameters but also for improving the overall quality of life for patients with diabetes. Awareness among healthcare providers regarding these manifestations and treatment options is often low, which underscores the importance of optimal management strategies [39].

In conclusion, the impact of diabetes on the gastrointestinal system is profound, with potential complications affecting motility, secretion, and absorption. A multidisciplinary approach is vital in managing these complications, focusing on early detection, appropriate treatment strategies, and continuous monitoring to improve metabolic control and patient outcomes [27].

6.2 Effects on the Immune System ​

Diabetes mellitus significantly impacts various organ systems, with profound effects on the immune system being a critical area of concern. The pathology of diabetes-induced immune dysfunction is multifaceted, leading to an increased vulnerability to infections and complications across multiple organ systems.

One of the primary consequences of diabetes on the immune system is the impaired proliferation of immune cells and the induction of cellular senescence. This dysfunction mirrors the concept of "inflammaging," which refers to a persistent low-grade inflammation often observed in the elderly. In individuals with diabetes, this inflammatory state may heighten the risk of conditions such as rheumatoid arthritis and periodontitis at younger ages (Alexander et al., 2024) [41].

Diabetes affects the composition of bone marrow and alters lymphopoiesis, resulting in increased myeloid differentiation while reducing lymphoid differentiation. This shift compromises both the innate and adaptive immune responses, culminating in a diminished immune system response. Consequently, individuals with diabetes experience higher infection rates, reduced efficacy of vaccinations, and increased senescence of immune cells (Alexander et al., 2024) [41].

Furthermore, immune cell dysfunction plays a pivotal role in the development of diabetes complications. Impaired pathogen recognition and dysfunctional behavior of immune cells such as macrophages, neutrophils, and natural killer (NK) cells are significant defects observed in the innate immune response of diabetic patients. The dysregulation of the complement system and alterations in cytokine production further disrupt overall immune signaling, contributing to chronic inflammation and reduced pathogen clearance. These immune deficiencies exacerbate diabetes complications and increase susceptibility to infections (Saadh et al., 2025) [42].

In addition to these innate immune defects, adaptive immunity is also compromised in diabetes. The dysfunction of T and B cell subsets, including CD4+ T cells, CD8+ T cells, regulatory T cells, and B cells, has been documented. This dysregulation not only contributes to chronic inflammation but also reduces the overall immune competence, thereby complicating diabetes management and increasing the risk of severe complications (Saadh et al., 2025) [42].

Moreover, the immune system's response in diabetic patients is further complicated by the presence of chronic low-grade inflammation. This inflammatory state affects various tissues, leading to specific complications such as diabetic retinopathy and other organ-specific damages (Amorim et al., 2023) [36].

In summary, diabetes mellitus adversely affects the immune system by impairing the proliferation and function of immune cells, promoting cellular senescence, and inducing a state of chronic inflammation. These changes contribute to increased susceptibility to infections and complications, highlighting the need for targeted therapeutic strategies to address immune dysfunction in diabetic patients.

7 Conclusion ​

Diabetes mellitus is a systemic disease with profound implications for multiple organ systems, including the cardiovascular, renal, neurological, and ocular systems. The major findings of this report highlight the complex interplay between hyperglycemia, metabolic dysregulation, inflammation, and the development of organ-specific complications. The cardiovascular system is significantly affected by conditions such as diabetic cardiomyopathy and endothelial dysfunction, which increase the risk of morbidity and mortality among diabetic patients. Renal complications, particularly diabetic nephropathy, arise from a combination of metabolic and inflammatory processes, necessitating a multifaceted therapeutic approach to manage blood glucose levels and prevent further renal damage. Neurological complications, including diabetic neuropathy, reveal the extensive impact of diabetes on the nervous system, leading to significant impairments in quality of life. Ocular complications, notably diabetic retinopathy, underscore the systemic nature of diabetes-related damage, necessitating vigilant screening and management to prevent vision loss. The report also emphasizes the importance of addressing gastrointestinal and immune system complications, which are often overlooked but contribute significantly to the overall burden of diabetes. Future research directions should focus on identifying organ-specific therapeutic targets, exploring novel treatment modalities, and enhancing patient education to improve adherence to management strategies. A holistic approach to diabetes care is essential to mitigate the multifaceted complications associated with this chronic disease and to improve the quality of life for individuals living with diabetes.

References ​

  • [1] Huanxin Ding;Yun Zhang;Xiaomin Ma;Zhongwen Zhang;Qian Xu;Chuxuan Liu;Bingjun Li;Shuohui Dong;Linchuan Li;Jiankang Zhu;Mingwei Zhong;Guangyong Zhang. Bariatric surgery for diabetic comorbidities: A focus on hepatic, cardiac and renal fibrosis.. Frontiers in pharmacology(IF=4.8). 2022. PMID:36339532. DOI: 10.3389/fphar.2022.1016635.
  • [2] Stephanie Eid;Kelli M Sas;Steven F Abcouwer;Eva L Feldman;Thomas W Gardner;Subramaniam Pennathur;Patrice E Fort. New insights into the mechanisms of diabetic complications: role of lipids and lipid metabolism.. Diabetologia(IF=10.2). 2019. PMID:31346658. DOI: 10.1007/s00125-019-4959-1.
  • [3] David A Antonetti;Paolo S Silva;Alan W Stitt. Current understanding of the molecular and cellular pathology of diabetic retinopathy.. Nature reviews. Endocrinology(IF=40.0). 2021. PMID:33469209. DOI: 10.1038/s41574-020-00451-4.
  • [4] Khaled Benchoula;Ahmed Mediani;Wong Eng Hwa. The functions of Ca2+/calmodulin-dependent protein kinase II (CaMKII) in diabetes progression.. Journal of cell communication and signaling(IF=3.9). 2023. PMID:35551607. DOI: 10.1007/s12079-022-00680-4.
  • [5] Dinesh Selvarajah;Solomon Tesfaye. Central nervous system involvement in diabetes mellitus.. Current diabetes reports(IF=6.4). 2006. PMID:17118225. DOI: 10.1007/s11892-006-0075-y.
  • [6] Girish Talakatta;Mohsen Sarikhani;Jaseer Muhamed;K Dhanya;Bagganahalli S Somashekar;Padukudru Anand Mahesh;Nagalingam Sundaresan;P V Ravindra. Diabetes induces fibrotic changes in the lung through the activation of TGF-β signaling pathways.. Scientific reports(IF=3.9). 2018. PMID:30093732. DOI: 10.1038/s41598-018-30449-y.
  • [7] Zhen Chen;Qiangrong Liang;Yue Wu;Zijun Gao;Satoru Kobayashi;Joy Patel;Cairong Li;Fei Cai;Youhua Zhang;Chongsheng Liang;Hitoshi Chiba;Shu-Ping Hui. Comprehensive lipidomic profiling in serum and multiple tissues from a mouse model of diabetes.. Metabolomics : Official journal of the Metabolomic Society(IF=3.3). 2020. PMID:33067714. DOI: 10.1007/s11306-020-01732-9.
  • [8] Jiajing Hong;Shiqi Lu;Guohui Shan;Yaoran Yang;Bailin Li;Dongyu Yang. Application and Progression of Single-Cell RNA Sequencing in Diabetes Mellitus and Diabetes Complications.. Journal of diabetes research(IF=3.4). 2025. PMID:40135071. DOI: 10.1155/jdr/3248350.
  • [9] Brittany Law;Vennece Fowlkes;Jack G Goldsmith;Wayne Carver;Edie C Goldsmith. Diabetes-induced alterations in the extracellular matrix and their impact on myocardial function.. Microscopy and microanalysis : the official journal of Microscopy Society of America, Microbeam Analysis Society, Microscopical Society of Canada(IF=3.0). 2012. PMID:22221857. DOI: 10.1017/S1431927611012256.
  • [10] Jason C Kovacic;Jose M Castellano;Michael E Farkouh;Valentin Fuster. The relationships between cardiovascular disease and diabetes: focus on pathogenesis.. Endocrinology and metabolism clinics of North America(IF=4.2). 2014. PMID:24582091. DOI: .
  • [11] Zhao Zhong Chong;Kenneth Maiese. Mammalian target of rapamycin signaling in diabetic cardiovascular disease.. Cardiovascular diabetology(IF=10.6). 2012. PMID:22545721. DOI: 10.1186/1475-2840-11-45.
  • [12] Laurel A Grisanti. Diabetes and Arrhythmias: Pathophysiology, Mechanisms and Therapeutic Outcomes.. Frontiers in physiology(IF=3.4). 2018. PMID:30534081. DOI: 10.3389/fphys.2018.01669.
  • [13] Michael N Sack. Type 2 diabetes, mitochondrial biology and the heart.. Journal of molecular and cellular cardiology(IF=4.7). 2009. PMID:19217910. DOI: 10.1016/j.yjmcc.2009.02.001.
  • [14] Sergey Shityakov;Michiaki Nagai;Süleyman Ergün;Barbara M Braunger;Carola Y Förster. The Protective Effects of Neurotrophins and MicroRNA in Diabetic Retinopathy, Nephropathy and Heart Failure via Regulating Endothelial Function.. Biomolecules(IF=4.8). 2022. PMID:36009007. DOI: 10.3390/biom12081113.
  • [15] Marina Strocchi;Daniel J Hammersley;Brian P Halliday;Sanjay K Prasad;Steven A Niederer. Cardiac digital twins: a tool to investigate the function and treatment of the diabetic heart.. Cardiovascular diabetology(IF=10.6). 2025. PMID:40682127. DOI: 10.1186/s12933-025-02839-w.
  • [16] Grzegorz Gajos. Diabetes and cardiovascular disease: from new mechanisms to new therapies.. Polish archives of internal medicine(IF=4.7). 2018. PMID:29579035. DOI: 10.20452/pamw.4227.
  • [17] Anil Karihaloo. Anti-fibrosis therapy and diabetic nephropathy.. Current diabetes reports(IF=6.4). 2012. PMID:22644874. DOI: 10.1007/s11892-012-0290-7.
  • [18] Javier Donate-Correa;Ernesto Martín-Núñez;Mercedes Muros-de-Fuentes;Carmen Mora-Fernández;Juan F Navarro-González. Inflammatory cytokines in diabetic nephropathy.. Journal of diabetes research(IF=3.4). 2015. PMID:25785280. DOI: 10.1155/2015/948417.
  • [19] Antonio Rivero;Carmen Mora;Mercedes Muros;Javier García;Havidian Herrera;Juan F Navarro-González. Pathogenic perspectives for the role of inflammation in diabetic nephropathy.. Clinical science (London, England : 1979)(IF=7.7). 2009. PMID:19200057. DOI: 10.1042/CS20080394.
  • [20] Allan Flyvbjerg. The role of the complement system in diabetic nephropathy.. Nature reviews. Nephrology(IF=39.8). 2017. PMID:28262777. DOI: 10.1038/nrneph.2017.31.
  • [21] Jingxuan Shi;Xinze Liu;Yuanyuan Jiao;Jingwei Tian;Jiaqi An;Guming Zou;Li Zhuo. mTOR pathway: A key player in diabetic nephropathy progression and therapeutic targets.. Genes & diseases(IF=9.4). 2025. PMID:39717716. DOI: 10.1016/j.gendis.2024.101260.
  • [22] Hussein H Karnib;Fuad N Ziyadeh. The cardiorenal syndrome in diabetes mellitus.. Diabetes research and clinical practice(IF=7.4). 2010. PMID:20599286. DOI: 10.1016/j.diabres.2010.05.022.
  • [23] M F Figueira;G Monnerat-Cahli;E Medei;A B Carvalho;M M Morales;M E Lamas;R N da Fonseca;J Souza-Menezes. MicroRNAs: potential therapeutic targets in diabetic complications of the cardiovascular and renal systems.. Acta physiologica (Oxford, England)(IF=5.6). 2014. PMID:24837225. DOI: 10.1111/apha.12316.
  • [24] Randhir Singh;Lalit Kishore;Navpreet Kaur. Diabetic peripheral neuropathy: current perspective and future directions.. Pharmacological research(IF=10.5). 2014. PMID:24373831. DOI: .
  • [25] Dinesh Selvarajah;Iain D Wilkinson;Jennifer Davies;Rajiv Gandhi;Solomon Tesfaye. Central nervous system involvement in diabetic neuropathy.. Current diabetes reports(IF=6.4). 2011. PMID:21667355. DOI: 10.1007/s11892-011-0205-z.
  • [26] Natalie Strand;Meredith A Anderson;Sumedha Attanti;Benjamin Gill;Christopher Wie;Azizat Dawodu;Robert Pagan-Rosado;Monica W Harbell;Jillian A Maloney. Diabetic Neuropathy: Pathophysiology Review.. Current pain and headache reports(IF=3.5). 2024. PMID:38558164. DOI: 10.1007/s11916-024-01243-5.
  • [27] Mona Mohamed Ibrahim Abdalla. Enteric neuropathy in diabetes: Implications for gastrointestinal function.. World journal of gastroenterology(IF=5.4). 2024. PMID:38947292. DOI: 10.3748/wjg.v30.i22.2852.
  • [28] Nigel A Calcutt. Diabetic neuropathy and neuropathic pain: a (con)fusion of pathogenic mechanisms?. Pain(IF=5.5). 2020. PMID:32999525. DOI: 10.1097/j.pain.0000000000001922.
  • [29] Walter N Kernan;Rachel Forman;Silvio E Inzucchi. Caring for Patients With Diabetes in Stroke Neurology.. Stroke(IF=8.9). 2023. PMID:36541212. DOI: 10.1161/STROKEAHA.122.038163.
  • [30] A J Scheen. Central nervous system: a conductor orchestrating metabolic regulations harmed by both hyperglycaemia and hypoglycaemia.. Diabetes & metabolism(IF=4.7). 2010. PMID:21211733. DOI: 10.1016/S1262-3636(10)70464-X.
  • [31] Marina Bogush;Nathan A Heldt;Yuri Persidsky. Blood Brain Barrier Injury in Diabetes: Unrecognized Effects on Brain and Cognition.. Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology(IF=3.5). 2017. PMID:28555373. DOI: 10.1007/s11481-017-9752-7.
  • [32] Ritu;Ramesh K Goyal;Sonia Narwal;Alok Bhatt;Renu Sehrawat;Pooja Devi;Monica Gulati;Rajeev K Singla. Role of MMP-9 and NF-κB in Diabetic Retinopathy: Progression and Potential Role of Bioflavonoids in the Mitigation of Diabetic Retinopathy.. Current medicinal chemistry(IF=3.5). 2025. PMID:38818917. DOI: 10.2174/0109298673316493240527113707.
  • [33] Ning Cheung;Tien Y Wong. Diabetic retinopathy and systemic vascular complications.. Progress in retinal and eye research(IF=14.7). 2008. PMID:18249026. DOI: 10.1016/j.preteyeres.2007.12.001.
  • [34] Stephen H Sinclair;Stanley S Schwartz. Diabetic Retinopathy-An Underdiagnosed and Undertreated Inflammatory, Neuro-Vascular Complication of Diabetes.. Frontiers in endocrinology(IF=4.6). 2019. PMID:31920963. DOI: 10.3389/fendo.2019.00843.
  • [35] Siqi Wang;Hongyu Yang;Jiaying Zheng;Aiyang Tong;Sen Mu;Dongkai Wang;Ming Zhao;Ji Li. Recent advances and prospects of nanoparticle-based drug delivery for diabetic ocular complications.. Theranostics(IF=13.3). 2025. PMID:40093887. DOI: 10.7150/thno.108691.
  • [36] Madania Amorim;Beatriz Martins;Rosa Fernandes. Immune Fingerprint in Diabetes: Ocular Surface and Retinal Inflammation.. International journal of molecular sciences(IF=4.9). 2023. PMID:37372968. DOI: 10.3390/ijms24129821.
  • [37] S Lightman. Does aldose reductase have a role in the development of the ocular complications of diabetes?. Eye (London, England)(IF=3.2). 1993. PMID:7607342. DOI: 10.1038/eye.1993.56.
  • [38] K Co Shih;K S-L Lam;L Tong. A systematic review on the impact of diabetes mellitus on the ocular surface.. Nutrition & diabetes(IF=5.2). 2017. PMID:28319106. DOI: 10.1038/nutd.2017.4.
  • [39] Babu Krishnan;Shithu Babu;Jessica Walker;Adrian B Walker;Joseph M Pappachan. Gastrointestinal complications of diabetes mellitus.. World journal of diabetes(IF=4.6). 2013. PMID:23772273. DOI: 10.4239/wjd.v4.i3.51.
  • [40] Piero Portincasa;Leonilde Bonfrate;David Q-H Wang;Gema Frühbeck;Gabriella Garruti;Agostino Di Ciaula. Novel insights into the pathogenic impact of diabetes on the gastrointestinal tract.. European journal of clinical investigation(IF=3.6). 2022. PMID:35904418. DOI: 10.1111/eci.13846.
  • [41] Michael Alexander;Eric Cho;Eiger Gliozheni;Yusuf Salem;Joshua Cheung;Hirohito Ichii. Pathology of Diabetes-Induced Immune Dysfunction.. International journal of molecular sciences(IF=4.9). 2024. PMID:39000211. DOI: 10.3390/ijms25137105.
  • [42] Mohamed J Saadh;Omer Qutaiba B Allela;Radhwan Abdul Kareem;Ashishkumar Kyada;H Malathi;Deepak Nathiya;Deepak Bhanot;Hayder Naji Sameer;Atheer Khdyair Hamad;Zainab H Athab;Mohaned Adil. Immune cell dysfunction: A critical player in development of diabetes complications.. Current research in translational medicine(IF=3.0). 2025. PMID:40339429. DOI: 10.1016/j.retram.2025.103510.

MaltSci Intelligent Research Services ​

Search for more papers on MaltSci.com ​

Diabetes · Multiple Organ Systems · Pathophysiological Mechanisms · Complications · Management Strategies

© 2025 MaltSci